VectivBio Holding AG (VECT)
16.87
0.02 (0.12%)
Jul 07, 2023, 7:59 PM - Market open
0.12% (1D)
| Bid | n/a |
| Market Cap | 1.06B |
| Revenue (ttm) | 676K |
| Net Income (ttm) | -71.98M |
| EPS (ttm) | -2.1 |
| PE Ratio (ttm) | -8.033333333333333 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 127,653 |
| Avg. Volume (20D) | 1,100,434 |
| Open | 16.80 |
| Previous Close | 16.85 |
| Day's Range | 16.80 - 16.88 |
| 52-Week Range | 4.25 - 16.98 |
| Beta | 0.10 |
About VECT
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 8, 2021
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol VECT
Website https://vectivbio.com